Cardiovascular DiseasesSMINCT07693712
Senescence in Myocardial Infarction
An observational study of Cardiovascular Diseases and Coronary Artery Disease, run by South Tees Hospitals NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
The investigators of this study have found that after a heart attack, some heart cells rapidly age (become senescent) and release proteins that make the heart disease worse. The investigators of this study would like to check for these aged-cell proteins in participants who have coronary artery bypass graft (CABG)… Read more about this study
- Who is it for?
- Ages 40 to 80 years
- Conditions the study is for
- Cardiovascular Diseases, Coronary Artery Disease, Aging
- How many people
- 22 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 8 May 2024to 26 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population are male and female patients undergoing CABG surgery. There will be 70 patients split between two groups of 35 patients each. Group I will be patients who are undergoing coronary artery bypass graft surgery for recent Non-ST segment elevation myocardial infarction (NSTEMI), and Group II will be patients undergoing CABG for stable coronary artery disease
Who may be able to join
- Male and female patients aged 40 to 80 years old undergoing coronary artery bypass graft surgery for myocardial infarction or for stable angina.
Who cannot join
- patients with ST-elevation myocardial infarction requiring coronary angioplasty
- patients who have had previous cardiac surgery
- patients who have evidence of ongoing heart failure,
- a left ventricular ejection fraction of less than 30%
- need for pre-operative mechanical cardiac support.
- Individuals with pre-existing acute kidney injury
- Sepsis
- >Stage 4 chronic kidney disease
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
South Tees Hospitals NHS Foundation Trust
Middlesbrough, TS4 3BW
About this study
Official title: Coronary Artery Bypass Surgery After Myocardial Infarction: Identifying Clinical Outcomes by Analysing the Senescence Associated Secretory Phenotype
The investigators of this study have found that after a heart attack, some heart cells rapidly age (become senescent) and release proteins that make the heart disease worse.
The investigators of this study would like to check for these aged-cell proteins in participants who have coronary artery bypass graft (CABG) surgery after a recent heart attack or to treat more stable heart disease.
The investigators will do this by taking blood samples and a sample of normally discarded heart tissue from each group of participants. This might help tell us who is at the highest risk of developing heart disease and how people recover from a heart attack.
Read the detailed description
The goal of this observational study is to compare the levels of aged-cell proteins in participants who have coronary artery bypass graft (CABG) surgery after a recent heart attack or to treat more stable heart disease.
The main questions it aims to answer are:
- To identify if there is an increased in aged-cell proteins in participants who have had a myocardial infarction and are having CABG surgery, compared to participants who are having CABG surgery for more stable heart disease.
- To establish if levels of these aged-cell proteins can predict outcomes for these patients, and if they correlate with other markers of heart disease.
The investigators will do this by taking blood samples and a sample of normally discarded heart tissue from each group of participants. This might help inform who is at the highest risk of developing heart disease and how patients recover from a heart attack.
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Aging, Atherosclerosis, Myocardial Infarction, Inflammation
- Medical subject headings
- Cardiovascular Diseases, Coronary Artery Disease, Atherosclerosis, Myocardial Infarction, Inflammation, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Myocardial Infarction Group | Patients who are undergoing CABG surgery for Non-ST segment elevation myocardial infarction (NSTEMI) | |
| Stable Angina Group | Patients who are undergoing CABG surgery for stable angina |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increase in senescent myocardial cells and senescence-associated secretory phenotype (SASP).
Blood samples taken to measure expression of a range of biomarkers.
Measured: From baseline to 6 weeks.
Secondary outcomes (3)
Correlation of senescence and SASP with clinical outcomes
Measures include incidences of mortality, stroke, duration of inotrope and vasopressor administration and other markers of myocardial disease, including troponins.
Measured: From baseline to 6 weeks
Progression of chronic cardiovascular disease
Progression of chronic cardiovascular disease will be determined using serum NT-proBNP at 6 weeks post surgery
Measured: baseline to 6 weeks
Clinical outcomes post surgery
Clinical outcomes associated with poorer recovery from MI
Measured: Baseline to 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2026
- Study start8 May 2024
- Primary completion26 Feb 2026
- Study completion26 Feb 2026
Why it stopped: Staffing challenges and subsequent withdrawal of funding.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- South Tees Hospitals NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Newcastle University
- Responsible party
- Sponsor
- Investigators
- Gavin Richardson, Principal investigator, Newcastle UniversityEnoch Akowuah, Principal investigator, South Tees Hospitals NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07693712
- Sponsor's protocol ID
- ACU010
- Acronym
- SMI
- Status last verified
- Jul 2026
- First submitted
- 8 Jun 2024
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Dookun E, Walaszczyk A, Redgrave R, Palmowski P, Tual-Chalot S, Suwana A, Chapman J, Jirkovsky E, Donastorg Sosa L, Gill E, Yausep OE, Santin Y, Mialet-Perez J, Andrew Owens W, Grieve D, Spyridopoulos I, Taggart M, Arthur HM, Passos JF, Richardson GD. Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery. Aging Cell. 2020 Oct;19(10):e13249. doi: 10.1111/acel.13249. Epub 2020 Sep 29.
PubMed 32996233Walaszczyk A, Dookun E, Redgrave R, Tual-Chalot S, Victorelli S, Spyridopoulos I, Owens A, Arthur HM, Passos JF, Richardson GD. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell. 2019 Jun;18(3):e12945. doi: 10.1111/acel.12945. Epub 2019 Mar 28.
PubMed 30920115Redgrave R, Dookun E, Booth L, Folaranm O, Tual-Chalot S, Gill J, Owens A, Spyridopoulos I, Passos J, Richardson G. Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction. Res Sq [Preprint]. 2023 Apr 10:rs.3.rs-2776501. doi: 10.21203/rs.3.rs-2776501/v1.
PubMed 37090497
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Coronary Artery Bypass Surgery After Myocardial Infarction: Identifying Clinical Outcomes by Analysing the Senescence Associated Secretory Phenotype
- ClinicalTrials.gov ID
- NCT07693712
- Acronym / sponsor ID
- SMI / ACU010
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Aging, Atherosclerosis, Myocardial Infarction, Inflammation
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Staffing challenges and subsequent withdrawal of funding.
- Enrolment
- 22 participants (actual)
- Lead sponsor
- South Tees Hospitals NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Newcastle University
- Study start
- 8 May 2024 (actual)
- Primary completion
- 26 Feb 2026 (actual)
- Study completion
- 26 Feb 2026 (actual)
- First posted
- 9 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators of this study have found that after a heart attack, some heart cells rapidly age (become senescent) and release proteins that make the heart disease worse.
The investigators of this study would like to check for these aged-cell proteins in participants who have coronary artery bypass graft (CABG) surgery after a recent heart attack or to treat more stable heart disease.
The investigators will do this by taking blood samples and a sample of normally discarded heart tissue from each group of participants. This might help tell us who is at the highest risk of developing heart disease and how people recover from a heart attack.
Detailed description
The goal of this observational study is to compare the levels of aged-cell proteins in participants who have coronary artery bypass graft (CABG) surgery after a recent heart attack or to treat more stable heart disease.
The main questions it aims to answer are:
- To identify if there is an increased in aged-cell proteins in participants who have had a myocardial infarction and are having CABG surgery, compared to participants who are having CABG surgery for more stable heart disease.
- To establish if levels of these aged-cell proteins can predict outcomes for these patients, and if they correlate with other markers of heart disease.
The investigators will do this by taking blood samples and a sample of normally discarded heart tissue from each group of participants. This might help inform who is at the highest risk of developing heart disease and how patients recover from a heart attack.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Myocardial Infarction Group | – | –Patients who are undergoing CABG surgery for Non-ST segment elevation myocardial infarction (NSTEMI) |
| Stable Angina Group | – | –Patients who are undergoing CABG surgery for stable angina |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population are male and female patients undergoing CABG surgery. There will be 70 patients split between two groups of 35 patients each. Group I will be patients who are undergoing coronary artery bypass graft surgery for recent Non-ST segment elevation myocardial infarction (NSTEMI), and Group II will be patients undergoing CABG for stable coronary artery disease
Key inclusion criteria (1 listed)
- Male and female patients aged 40 to 80 years old undergoing coronary artery bypass graft surgery for myocardial infarction or for stable angina.
Key exclusion criteria (8 listed)
- patients with ST-elevation myocardial infarction requiring coronary angioplasty
- patients who have had previous cardiac surgery
- patients who have evidence of ongoing heart failure,
- a left ventricular ejection fraction of less than 30%
- need for pre-operative mechanical cardiac support.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Increase in senescent myocardial cells and senescence-associated secretory phenotype (SASP).
Time frame: From baseline to 6 weeks.
Blood samples taken to measure expression of a range of biomarkers.
3 secondary outcomes
Correlation of senescence and SASP with clinical outcomes
Time frame: From baseline to 6 weeks
Progression of chronic cardiovascular disease
Time frame: baseline to 6 weeks
Clinical outcomes post surgery
Time frame: Baseline to 6 weeks
Results and safety
The study was stopped early (reason given: Staffing challenges and subsequent withdrawal of funding.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Background: PubMed 32996233Dookun E, Walaszczyk A, Redgrave R, Palmowski P, Tual-Chalot S, Suwana A, Chapman J, Jirkovsky E, Donastorg Sosa L, Gill E, Yausep OE, Santin Y, Mialet-Perez J, Andrew Owens W, Grieve D, Spyridopoulos I, Taggart M, Arthur HM, Passos JF, Richardson GD. Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery. Aging Cell. 2020 Oct;19(10):e13249. doi: 10.1111/acel.13249. Epub 2020 Sep 29.
- Background: PubMed 30920115Walaszczyk A, Dookun E, Redgrave R, Tual-Chalot S, Victorelli S, Spyridopoulos I, Owens A, Arthur HM, Passos JF, Richardson GD. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell. 2019 Jun;18(3):e12945. doi: 10.1111/acel.12945. Epub 2019 Mar 28.
- Background: PubMed 37090497Redgrave R, Dookun E, Booth L, Folaranm O, Tual-Chalot S, Gill J, Owens A, Spyridopoulos I, Passos J, Richardson G. Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction. Res Sq [Preprint]. 2023 Apr 10:rs.3.rs-2776501. doi: 10.21203/rs.3.rs-2776501/v1.
- Individual participant dataSharing planned: No
Related trials for Cardiovascular Diseases
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2/3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart Failure, Left Ventricular Systolic Dysfunction
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Active, not recruitingPhase 4
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Coronary Artery Disease
Active, not recruiting
VOLT CE Mark Study
Atrial Arrhythmia, Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gavin Richardson principal investigator
Newcastle University
Enoch Akowuah principal investigator
South Tees Hospitals NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Coronary Artery Disease, run by South Tees Hospitals NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Staffing challenges and subsequent withdrawal of funding.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increase in senescent myocardial cells and senescence-associated secretory phenotype (SASP). (time frame: From baseline to 6 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07693712, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.